Alzheimer's Drug Discovery Foundation (ADDF)

Founded in 1998 by co-chairmen Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation (ADDF) is the only charity solely focused on finding drugs for Alzheimer’s.

Subsidy: $50,000-100,000 for epidemiological analyses; up to $3,000,000 for clinical trials

Funding rate: 100%

Deadlines: 1st stage (LOI): 5 February 2021, 28 May 2021, 1 October 2021

2nd stage (full proposal): 16 April 2021, 30 July 2021, 3 December 2021

Project duration: Multi-year; potential for follow-on funding

Consortium: Open to researchers, clinicians, and postdoctoral fellows in the U.S. and worldwide working at: academic medical centers and universities or nonprofits. Biotechnology companies that demonstrate a clear need for funding, and existing companies and startups are both eligible. Funding is provided through mission-related investments that require return on investment based upon scientific and/or business milestones.

Scope: The ADDF seeks to support comparative effectiveness research, prevention clinical trials, and epidemiological studies that probe whether the use or choice of drugs alters the risk for dementia or cognitive decline.

Specifically, the Prevention Beyond the Pipeline program supports:

  • Studies Leveraging the Consortium of Cohorts for Alzheimer’s Prevention Action (CAPA);
  • Comparative Effectiveness Research;
  • Studies of Cognitive Decline and Cognitive Reserve.

To get free funding updates, including with regard to the ADDF, subscribe to Catalyze Alerts.

About Alzheimer’s Drug Discovery Foundation (ADDF)

The ADDF focuses on translating the knowledge they have gained about the causes of Alzheimer’s disease into drugs to conquer it. They support an underfunded area—preclinical drug discovery and early-stage clinical trials of potential drug targets—that is often called the “valley of death” because it’s where good ideas go to die. These projects hold great promise, but also great risk.

And most are not far enough along in the drug development pipeline to attract financial support from the pharmaceutical industry, federal funders, or other major partners. By assuming the risk and bridging this critical gap in funding, the ADDF enables leading scientists to pursue pioneering ideas to cure Alzheimer’s disease that would otherwise go unexplored.

Visit the ADDF website for more information


Get funding, make impact

Whether you’re an academic or entrepreneur, we craft the roadmap you need to take on the challenges present in finding funding and reaching your market. With over 10 years of experience, we are your gateway to European funding, and beyond.

  • Fund. What if funding wasn’t a barrier to innovation? We guide you through the way of finding and obtaining funds.
  • Grow. What if your journey was clear? Get the best support for your grant journey.
  • Manage. What if you only had to focus on R&D? We provide the support you need to get your innovation on the market.

More about our consulting services

Catalyze Figure Ovals Lightgray

A must-have if you’re interested in getting your business to the next level